Comparing two drug combinations for recurrent ovarian cancer after PARP inhibitor treatment
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether a new drug combination (sacituzumab govitecan plus bevacizumab) works better than the usual chemotherapy for ovarian cancer that has come back after platinum treatment and PARP inhibitor maintenance. It may offer a new option for people with certain genetic markers (BRCA mutations or HRD).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian cancer that is high-grade serous or endometrioid (including fallopian tube or primary peritoneal cancer).
- Your cancer is platinum-sensitive, meaning it responded to platinum chemo and then came back at least 6 months after your last platinum dose.
- You have already taken a PARP inhibitor (like olaparib, niraparib, or rucaparib) as maintenance after first-line treatment, and your cancer has progressed on that. You cannot have had any other treatment in between.
- You have a BRCA1 or BRCA2 mutation (inherited or in the tumor) or a test showing homologous recombination deficiency (HRD).
- You have not had topoisomerase-I inhibitors (a type of chemo) before, and you have recovered from side effects of prior treatments.
- You are at least 18 years old, not pregnant, and have adequate organ function (kidney, liver, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs — sacituzumab tirumotecan (which attacks cancer cells) and bevacizumab (which cuts off blood supply to tumors) — for ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination helps shrink or slow the cancer.
This trial tests a new drug (HS-20089) combined with another drug (bevacizumab) for women whose ovarian cancer has returned after responding to platinum-based chemotherapy. The goal is to see if this combination helps control the cancer better than standard options.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
Hear when a new Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.